'Silent' cerebral infarction is associated with hypercoagulability, endothelial cell damage, and high Lp(a) levels in elderly Japanese

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 16, Issue 6, 1996, Pages 734-741

  Kario, Kazuomi ^a,b,c   Matsuo, Takefumi ^b   Kobayashi, Hiroko ^b   Asada, Reiko ^b   Matsuo, Miyako ^b  

^a Awaji Hokudan Public Clinic   (Japan)

^b HYOGO PREFECTURAL AWAJI HOSPITAL   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

elderly; endothelial cell damage; hypercoagulability; lipoprotein(a); silent lacunar stroke

Indexed keywords

CHOLESTEROL; CREATININE; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LIPOPROTEIN A; PROTHROMBIN; THROMBOMODULIN; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BRAIN INFARCTION; CELL DAMAGE; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STROKE;

EID: 0029941566     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.16.6.734     Document Type: Article

References (51)

1. Marmot MG, Smith GD. Why are the Japanese living longer? Br Med J. 1989;299:1547-1551.
2. Sherman DG, Hart RG. Stroke and transient ischemic attack: thromboembolism and antithrombotic therapy. In: Fuster V, Verstraete M, eds. Thrombosis in Cardiovascular Disorders. Philadelphia, Pa: WB Saunders Co; 1992:409-422.
3. Feinberg WM, Bruck DC, Ring ME, Corrigan JJ. Hemostatic markers in acute stroke. Stroke. 1989;20:592-597.
4. Ono N, Koyama T, Suehiro A, Oku K, Fujitake K, Kakishita E. Clinical significance of new coagulation and fibrinolytic markers in ischemic stroke. Stroke. 1991;22:1369-1373.
5. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med. 1993; 118:956-963.
6. Martinez HR, Rangel-Guerra RA, Marfil LJ. Ischemic stroke due to deficiency of coagulation inhibitors: report of 10 young adults. Stroke. 1993;24:19-25.
7. Fon EA, Mackey A, Côté R, Wolfson C, McIlraith DM, Leclere J, Bourque F. Hemostatic markers in acute transient attacks. Stroke. 1994;25:282-286.
8. Kario K, Matsuo T. High factor-VII activity in the elderly is related to vascular disease through activation of the coagulation system. J Cardiovasc Risk. 1994;1:165-171.
9. Murai A, Miyahara T, Fujimoto N, Matsuda M, Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis. 1986;59:199-204.
10. Zenker G, Koltringer P, Bone G, Niederkorn K, Pfeiffer K, Jurgens G. Lipoprotein (a) as a strong indicator for cerebrovascular disease. Stroke. 1986;17:942-945.
11. Woo J, Lau E, Lam CWK, Kay R, Wong HY, Teoh R, Nichoils MG. Hypertension, lipoprotein (a), and apolipoprotein A-I as risk factors for stroke in the Chinese. Stroke. 1991;22:203-208.
12. Shintani S, Kikuchi S, Hamaguchi H, Shiigai T. High serum lipoprotein (a) levels are an independent risk factor for cerebral infarction. Stroke. 1993;24:965-969.
13. Nakayama M, Shinohara Y, Nagayama T. Lipoprotein (a) and ischemic cerebrovascular disease in young adults. Stroke. 1994;25: 74-78.
14. Scott J. Lipoprotein(a): thrombotic and atherogenic. Br Med J. 1991;21:663-664.
15. Dahlén GH. Lp(a) lipoprotein in cardiovascular disease. Atherosclerosis. 1994;108:111-126.
16. Kario K, Matsuo T, Imiya M, Kayaba K, Kuroda T, Nago N, Matsuo H, Shimada K. Close relation between lipoprotein (a) levels and atherothrombotic disease in Japanese subjects >75 years of age. Am J Cardiol. 1994;73:1187-1190.
17. Shimada K, Kawamoto A, Matsubayashi K, Ozawa T. Silent cerebrovascular disease in the elderly: correlation with ambulatory pressure. Hypertension. 1990;16:692-699.
18. Hougaku H, Matsumoto M, Kitagawa K, Harada K, Oku N, Itoh T, Maeda H, Handa N, Kamada T. Silent cerebral infarction as a form of hypertensive target organ damage in the brain. Hypertension. 1992;20:816-820.
19. Kawamoto A, Shimada K, Matsubayashi K, Nishinaga M, Kimura S, Ozawa T. Factors associated with silent multiple lacunar lesions on magnetic resonance imaging in asymptomatic elderly hypertensive patients. Clin Exp Pharmacol Physiol. 1991;18:605-610.
20. National Institute of Neurological Disorders and Stroke Ad Hoc Committee (Whisnant JP, Basford JR, Bernstein EF, Cooper ES, Dyken ML, Easton JD, Little JR, Marier JR, Millikan CH, Petito CK, Price TR, Raichle ME, Robertson JT, Thiele B, Walker MD, Zimmerman RA). Classification of cerebrovascular disorders III. Stroke. 1990;21:637-676.
21. Kiyohara T, Ueda K, Hasuo Y, Wada J, Kawano H, Kato I, Shinkawa A, Ohmura T, Iwamoto H, Nakayama K, Omae T, Fijishima M. Type-specific incidence of cerebral infarction and its changing pattern during the long-term prospective population survey in the Hisayama town, Japan. Stroke. 1990;21(suppl I):I-35. Abstract.
22. Kario K, Matsuo T, Kodama K, Nakao K, Asada R. Reduced erythropoietin secretion in senile anemia. Am J Hematol. 1992;41: 252-257.
23. Kario K, Matsuo T. Relation between sialic acid concentrations and the haemostatic system in the elderly. Br Med J. 1993;306: 1650-1651.
24. Bauer KA, Goodman TL, Kass BL, Rosenberg RD. Elevated factor Xa activity in blood of asymptomatic patients with congenital antithrombin III deficiency. J Clin Invest, 1985;76:826-836.
25. Kario K, Matsuo T, Yamada T, Nakao K, Shimano C, Matsuo M. Factor VII hyperactivity in chronic dialysis patients. Thromb Res. 1992;67:105-113.
26. Rothrock JF, Lyden PD, Hesselink JR, Brown JJ, Healy ME. Brain magnetic resonance imaging in the evaluation of lacunar stroke. Stroke. 1987;18:781-786.
27. Farmer JA, Gotto AM Jr. Risk factors for coronary artery disease. In: Braunwald E, ed. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, Pa: WB Saunders Co; 1992:1125-1160.
28. Tohgi H, Yamanouchi H, Murakami M, Yameyama M. Importance of the hematocrit as a risk factor in cerebral infarction. Stroke. 1978; 9:369-374.
29. Expert Panel on Detection, Education, and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Education, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).JAMA. 1993;265:3015-3023.
30. Sadler EJ. von Willebrand factor. J Biol Chem. 1991;266: 22777-22780.
31. Ishii H, Nakano M, Tsubouchi J, Ishikawa T, Uchiyama H, Hiraishi S, Tahara C, Miyajima Y, Kazama M. Establishment of enzyme immunoassay of human thrombomodulin in plasma and urine using monoclonal antibodies. Thromb Haemost. 1990;63:157-162.
32. Ishii H, Uchiyama H, Kazama M. Soluble thrombomodulin antigen in conditioned medium is increased by damage of endothelial cells. Thromb Haemost. 1991;65:618-623.
33. Stehouwer CDA, Nauta JJP, Zeldenrust GC, Hackeng WHL, Donker AJM, den Ottolander GJH. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet. 1992;340:319-323.
34. Iwashima Y, Sato T, Watanabe K, Ooshima E, Hiraishi S, Ischii H, Kazama M, Makino I. Elevation of plasma thrombomodulin level in diabetic patients with early diabetic nephropathy. Diabetes. 1990;39: 983-988.
35. Mettinger KL. A study of hemostasis in ischemic cerebrovascular disease, I: abnormalities in factor VIII and antithrombin. Thromb Res. 1982;26:182-192.
36. Takahashi H, Ito S, Hanano M, Wada K, Niwano H, Seki Y, Shibata A. Circulating thrombomodulin as a novel endothelial cell marker: comparison of its behavior with von Willebrand factor and tissue-type plasminogen activator. Am J Hematol. 1992;41:32-39.
37. Wong VLY, Hofman FM, Ishii H, Fisher M. Regional distribution of thrombomodulin in human brain. Brain Res. 1991;556:1-5.
38. Meade TW. The epidemiology of atheroma, thrombosis and ischaemic heart disease. In: Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD, eds. Haemostasis and Thrombosis. London, England: Churchill Livingstone Inc; 1994:1199-1227.
39. Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Hennekens CH. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancer. 1993;341:1165-1168.
40. Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet. 1994;343:940-943.
41. McLean JW, Tomlinson JE, Kuang W-J, Eaton DL, Chen EY, Fless GM, Scanu AM, Lawn RM. cDNA sequence of human apolipoprotein (a) is homologous to plasminogen. Nature. 1987;300: 132-137.
42. Nago N, Kayaba K, Hiraoka J, Matsuo H, Goto T, Kario K, Tsutsumi A, Nakamura Y, Igarashi M. Lipoprotein (a) levels in the Japanese population: influence of age and sex, and relation to atherosclerotic risk factors - the Jichi Medical School Cohort Study. Am J Epidemiol. 1995;141:815-821.
43. Kario K, Nago N, Kayaba K, Saegusa T, Matsuo H, Goto T, Tsutsumi A, Ishikawa S, Kuroda T, Miyamoto T, Matsuo T, Shimada K, on behalf of the JMS Cohort Study Group. Characteristics of the insulin resistance syndrome in a Japanese population: the Jichi Medical School Cohort Study. Arterioscler Thromb Vasc Biol. 1996;16:269-274.
44. Marcovina SM, Albers JJ, Jacobs DR Jr, Perkins LL, Lewis CE, Howard BV, Savage P. Lipoprotein[a] concentrations and apolipoprotein[a] phenotypes in Caucasians and African Americans: the CARDIA Study. Arterioscler Thromb. 1993;13:1037-1045.
45. Schreiner PJ, Morrisett JD, Sharrett AR, Patsch W, Tyroler HA, Wu K, Heiss G. Lipoprotein[a] as a risk factor for preclinical atherosclerosis. Arterioscler Thromb. 1993;13:826-833.
46. Jenner JL, Ordovas JM, Lamon-Fava S, Schaefer MM, Wilson PWF, Castelli WP, Schaefer EJ. Effect of age, sex, and menopausal status on plasma lipoprotein(a) levels: the Framingham Offspring Study. Circulation. 1993;87:1135-1141.
47. Desmarais RL, Sarembock IJ, Ayers CR, Vernon SM, Powers ER, Gimple LW. Elevated serum lipoprotein(a) is a risk factor for clinical recurrence after coronary balloon angioplasty. Circulation. 1995;91:1403-1409.
48. Kario K, Matsuo T, Matsuo M, Koide M, Yamada T, Nakamura S, Sakata T, Kato H, Miyata T. Marked increase of activated factor VII in uremic patients. Thromb Haemost. 1995;73:763-767.
49. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T. Activation of tissue factor-induced coagulation and endothelial cell dysfunction of non-insulin-dependent diabetic patients with micro-albuminuria. Arterioscler Thromb Vase Biol. 1995;15:1114-1120.
50. Kario K, Matsuo T, Kobayashi H, Matsuo M, Asada R, Koide M. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Haemost. 1995; 74:1020-1024.
51. Kario K, Matsuo T, Kobayashi H, Matsuo M, Sakata T, Miyata T, Shimada K. Factor VII hyperactivity and endothelial cell damage are found in elderly hypertensives only when concomitant with microalbuminuria. Arterioscler Thromb Vasc Biol. 1996;16:455-461.